Literature DB >> 105067

Complement-mediated phagocytosis of Pseudomonas aeruginosa.

P K Peterson, Y Kim, D Schmeling, M Lindemann, J Verhoef, P G Quie.   

Abstract

The nature of the opsonic factors in nonimmune human serum for six blood culture isolates of Pseudomonas aeruginosa was investigated by measuring uptake of [3H] adenine-labeled bacteria by human PMNs. Normal human serum, C2- and C4-deficient sera, zymosan-treated serum, and immunoglobulin-deficient sera were used as opsonic sources. Heat inactivation of each of these serum sources markedly reduced its opsonic capacity for all Pseudomonas strains, suggesting that the serum C system was essential for opsonization. Five strains were opsonized in the absence of the classical C pathway; however, kinetic studies revealed that opsonization proceeded at a faster rate when the classical pathway was present. In spite of markedly reduced factor B and C3 levels, zymosan-treated serum retained significant opsonic activity for one of the strains tested. Four strains were poorly opsonized by immunoglobulin-deficient serum, and C activation by these strains appeared to depend upon the presence of antibodies. Two strains, however, were effectively opsonized in a relative absence of antibodies. Thus, in the nonimmune state, phagocytosis of P. aeruginosa is mediated primarily via the C system, and antibodies appear to play a role in the opsonization of some but perhaps not all Pseudomonas strains.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 105067

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  16 in total

Review 1.  Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.

Authors:  Colleen S Curran; Thomas Bolig; Parizad Torabi-Parizi
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

2.  Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.

Authors:  G B Pier; S E Bennett
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

3.  Phagocytosis and killing of Pseudomonas aeruginosa by mouse polymorphonuclear leukocytes in vitro promoted by antiserum to the slime glycolipoprotein.

Authors:  O Bishop; T Orr; P F Bartell
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

4.  Opsonization and phagocytosis of mucoid and non-mucoid Pseudomonas aeruginosa strains.

Authors:  T Meshulam; H A Verbrugh; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1982-04       Impact factor: 3.267

5.  Factor affecting the in vitro assessment of opsonization: a study of the kinetics of opsonization using the technique of phagocytic chemiluminescence.

Authors:  A J Williams; M J Hastings; C S Easmon; P J Cole
Journal:  Immunology       Date:  1980-12       Impact factor: 7.397

6.  Influence of serum concentration on opsonization by the classical and alternative complement pathways.

Authors:  R W Tofte; P K Peterson; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

7.  Nonopsonic phagocytosis of strains of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  D P Speert; F Eftekhar; M L Puterman
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

8.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

9.  The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia.

Authors:  Stacey L Mueller-Ortiz; Scott M Drouin; Rick A Wetsel
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  Biological effects of the interaction of staphylococcal alpha-toxin with human serum.

Authors:  C G Gemmell; P K Peterson; K Townsend; P G Quie; Y Kim
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.